BDBM185321 US10011588, Example 142::US10689373, Example 142::US9156829, 142

SMILES FC(F)(F)c1cnc(N[C@H]2CCC[C@@H]2NC(=O)c2ncccc2-n2nccn2)c(n1)C1CC1

InChI Key InChIKey=IIORDWZBRQCNIN-UHFFFAOYSA-N

Data  6 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 185321   

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185321(US9156829, 142 | US10011588, Example 142 | US10689...)
Affinity DataIC50: 12nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2016
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185321(US9156829, 142 | US10011588, Example 142 | US10689...)
Affinity DataIC50: 8.83E+3nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2016
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185321(US9156829, 142 | US10011588, Example 142 | US10689...)
Affinity DataIC50: 12nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185321(US9156829, 142 | US10011588, Example 142 | US10689...)
Affinity DataIC50: 8.83E+3nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185321(US9156829, 142 | US10011588, Example 142 | US10689...)
Affinity DataIC50: 12nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185321(US9156829, 142 | US10011588, Example 142 | US10689...)
Affinity DataIC50: 8.83E+3nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent